Lilly’s Retatrutide Produces Record 15.3% Weight Loss in Late-Stage Trial
Lead On March 19, 2026, Eli Lilly reported late-stage trial results showing its experimental drug retatrutide produced an average 15.3% body-weight reduction at the highest dose in a measure that includes patients who discontinued treatment. The results, disclosed to Bloomberg on March 19, 2026, exceed weight-loss outcomes seen in earlier trials of the company’s diabetes … Read more